Fate Therapeutics Inc (NASDAQ:FATE) Stock Price Up as Sentiment Worsens

December 8, 2017 - By Kurt Siggers

 Fate Therapeutics Inc (NASDAQ:FATE) Stock Price Up as Sentiment  Worsens

Sentiment for Fate Therapeutics Inc (NASDAQ:FATE)

Fate Therapeutics Inc (NASDAQ:FATE) institutional sentiment decreased to 1.43 in 2017 Q2. Its down -4.97, from 6.4 in 2017Q1. The ratio turned negative, as 33 institutional investors opened new and increased stock positions, while 23 reduced and sold their equity positions in Fate Therapeutics Inc. The institutional investors in our partner’s database now have: 25.76 million shares, down from 49.60 million shares in 2017Q1. Also, the number of institutional investors holding Fate Therapeutics Inc in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 12 Increased: 14 New Position: 19.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $174.66 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

The stock increased 6.35% or $0.25 during the last trading session, reaching $4.19. About 291,758 shares traded or 26.57% up from the average. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 166.12% since December 8, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.

Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on March, 15. They expect $-0.26 EPS, down 23.81 % or $0.05 from last year’s $-0.21 per share. After $-0.26 actual EPS reported by Fate Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Polaris Venture Management Co. V L.L.C. holds 8.29% of its portfolio in Fate Therapeutics, Inc. for 2.47 million shares. Ecor1 Capital Llc owns 2.54 million shares or 1.46% of their US portfolio. Moreover, 683 Capital Management Llc has 0.28% invested in the company for 588,237 shares. The California-based Redmile Group Llc has invested 0.28% in the stock. Kingdon Capital Management L.L.C., a New York-based fund reported 1.15 million shares.#img1#

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Ratings analysis reveals 100% of Fate Therapeutics’s analysts are positive. Out of 8 Wall Street analysts rating Fate Therapeutics, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4 while the high is $8. The stock’s average target of $7.33 is 74.94% above today’s ($4.19) share price. FATE was included in 9 notes of analysts from October 6, 2015. Wedbush maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Tuesday, November 8 with “Outperform” rating. The rating was initiated by TH Capital on Thursday, September 22 with “Buy”. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Buy” rating by BMO Capital Markets on Wednesday, November 1. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. The firm earned “Buy” rating on Thursday, September 22 by Roth Capital. The company was initiated on Tuesday, October 6 by Raymond James. Leerink Swann initiated the shares of FATE in report on Friday, September 8 with “Buy” rating. H.C. Wainwright reinitiated Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Thursday, October 12. H.C. Wainwright has “Buy” rating and $7 target. The stock has “Outperform” rating by Wells Fargo on Friday, December 4.

More recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Globenewswire.com which released: “Fate Therapeutics and University of California San Diego Launch Research …” on December 06, 2017. Also Seekingalpha.com published the news titled: “Fate Therapeutics’ (FATE) CEO Scott Wolchko on Q3 2017 Results – Earnings Call …” on November 02, 2017. Nasdaq.com‘s news article titled: “Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?” with publication date: December 05, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.